Biotech developing complement-targeting precision medicines (lead CTx001).
| Date | Round | Amount |
|---|---|---|
| Apr 2023 | Series A German biotech Complement Therapeutics raised a EUR72M Series A led by Gimv and Forbion. | $77M |
| Apr 2023 | Funding round Complement Therapeutics raised around EUR72M in April 2023 for its complement-mediated disease therapeutics. | $72M |